/en/sysglobalassets/global-assets/capabilities/lens_thick_light.svg

Schroder UK Public Private Trust plc

Tim Creed and Ben Wicks
Portfolio managers, Schroder UK Public Private Trust Plc

Overview of 20 largest investments as of 31 December 2020

Schroder UK Public Private Trust Plc invests in publicly listed and private companies which showcase the best in British innovation.

AMO Pharma

Healthcare

Private

Developer of drugs to treat rare or orphan diseases

AMO Pharma is a biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options. As well as developing AMO-02 for congenital myotonic dystrophy, the company is progressing AMO-01 as a clinical stage treatment for Phelan McDermid Syndrome and AMO-04 as a clinic ready potential medicine for Rett Syndrome and related disorders.

Atom Bank

Technology

Private

Provider of app-only banking services

Atom bank is the UK’s first bank built exclusively for mobile. It is redefining what a bank should be, making things easier, more transparent and better value. Atom currently offers savings accounts, mortgages and business loans.

 

Autolus Therapeutics

Healthcare

Public

Innovative biotech company developing next generation, programmed T cell therapies for the treatment of cancer

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

 

Beneveolent AI

Healthcare

Private

Technology company at the leading edge of developing and applying artificial intelligence for drug discovery and development

BenevolentAI creates and applies artificial intelligence (AI) and machine learning to transform the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process from hypothesis generation to late-stage clinical development. The Benevolent Platform® is used by scientists and technologists to find new ways to treat disease, improve the efficacy and lower the development time and costs of new treatments.

 

 

Carrick Therapeutics

Healthcare

Private

Pioneer of a unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer

Carrick Therapeutics is a biopharmaceutical company focusing on targeting key pathways in cancer progression and adaptive resistance.

 

Cequr

Healthcare

Private

Developer of simple-to-use insulin-delivery devices for people living with diabetes CeQur is commercialising advanced, simple-to-use insulin-delivery devices that make it easier for people living with diabetes to adhere to therapy and provide freedom from multiple daily insulin injections.

Federated Wireless

Technology

Private

Pioneer of shared spectrum services to the telecommunication industry

Founded in 2012, Federated Wireless has long led the industry in development of shared spectrum CBRS capabilities. The company’s partner ecosystem includes more than 40 device manufacturers and edge partners, all of which are dedicated to collaboration to advance development and proliferation of CBRS services. Federated Wireless’ customer base includes companies spanning the telecommunications, energy, hospitality, education, retail, office space, municipal and residential verticals, with use cases ranging from network densification and mobile offload to Private LTE and Industrial IoT.

Genomics

Healthcare

Private

Developer of a genomic database to find drug targets for serious diseases

Genomics plc is a health intelligence company that uses tools powered by genomics to transform disease risk prediction and drug discovery.  The company was founded in 2014 by four leading statistical and human geneticists at the University of Oxford with the vision of unlocking knowledge from population-scale genetics to make healthcare systems better for the individuals they serve. Backed by some of the leading investors in life sciences, Genomics has a team of over 80 people, primarily statistical and biological scientists and software engineers, with offices in Oxford, Cambridge, and Boston.   

HP Environmental Technologies Fund LP

Industrial

Private

Portfolio of venture and growth-stage industrial companies

HP Environmental Technologies Fund LP is the investment vehicle that acquired Ombu Group Limited, a specialist investor in early and growth stage environmental technologies

IDEX Biometrics Technology

Technology

Public

Leading provider of fingerprint identification technologies

IDEX Biometrics ASA is a leading provider of fingerprint identification technologies offering simple, secure and personal touch-free authentication. The technology enables people to make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings.

Immunocore

Healthcare

Private

Pioneering clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines

Immunocore is a pioneering T cell receptor biotechnology company, working to develop and commercialise a new generation of transformative medicines to address unmet needs. The Company’s most advanced programmes are in oncology and it has a rich pipeline of programmes in infectious and autoimmune diseases. Its lead programme, Tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma.

 

Inivata

Healthcare

Private

Leading innovator in the field of liquid biopsy, a transformative approach that identifies tiny amounts of cancer DNA in the blood of patients with cancer

Inivata is a leader in liquid biopsy, a transformative approach that identifies tiny amounts of cancer DNA in the blood of patients with cancer. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, at the University of Cambridge and is reinforced by multiple high calibre publications. Its lead product, InVisionFirst®-Lung, is commercially available and helps clinicians to make informed treatment decisions for patients with Lung cancer.

Kymab

Healthcare

Private

Innovative developer of human monoclonal antibody therapeutics

Kymab develops monoclonal antibody therapeutics for oncology and other disorders. Its proprietary platform allows for precise production of a diverse range of fully humanized monoclonal antibodies. Its pipeline include programs in oncology, immune disorders and several discovery stage programs for other indications.

 

Mafic

Industrials

Private

Leading global manufacturer of basalt fibre

Mafic is the only producer of continuous high quality basalt fibre in the United States and its production facility in Shelby, North Carolina is set to be the largest such facility in the world. Mafic was originally formed in 2011 for the production of advanced materials for the composite industry. It currently has manufacturing facilities in the US and Europe where it produces continuous and chopped basalt fibre and long fibre thermoplastic (LFT) resins.

 

Mission Therapeutics

Healthcare

Private

Developer of a first-in-class therapeutics platform providing positive impact on the lives of patients suffering from serious diseases

Mission Therapeutics has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. The company focuses on treatment of kidney disease, fibrosis, rare mitochondrial diseases, and neurodegenerative.

Nexeon

Industrials

Private

Leading developer of engineered silicon materials for battery applications

Nexeon is a leading developer of engineered silicon materials for battery applications. Nexeon’s lithium ion battery anode technology uses silicon to enhance or replace the traditional graphite anode technologies with the potential to improve the performance of the current Li-ion batteries used in electric vehicles and a wide range of consumer electronics.

Oxford Nanopore

Healthcare

Private

Technology company at the forefront of next generation DNA sequencing instrumentation

Oxford Nanopore Technologies is developing and commercialising a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins. The handheld MinION™ device, the high-throughput/high sample number PromethION™ and the GridION™ system are designed to provide novel qualities in molecular sensing such as real-time data streaming, improved simplicity, efficiency and scalability of workflows and direct analysis of the molecule of interest. The devices may be used in scientific research, personalised medicine, crop science, security and defence and environmental applications and a number of applications, methods and tools have been published by MinION users.

 

 

Reaction Engines

Industrials

Private

Developer of innovative high performance engine technologies to enable space and hypersonic travel

Reaction Engines is developing its innovative SABRE engine to enable space and hypersonic travel more efficieint and more accesible. Multiple applications are being spun off from this core vision creating a step change in performance and efficiency in an array of commercial industries.

 

Rutherford Health

Healthcare

Public

The UK's first network of cancer centres to offer proton beam therapy

Rutherford Health is at the vanguard of advancing cancer care. The company operates a network of four oncology centres across the UK known as the Rutherford Cancer Centres, offering a comprehensive range of cancer treatments to patients. The first centre in Newport, South Wales, was the first in the UK to offer high energy proton therapy. In addition, each centre also offers radiotherapy, chemotherapy, immunotherapy, diagnostic imaging and supportive care services.

Seedrs

Leading EU private growth equity fundraising and investment platform

Seedrs was the first regulated investment crowdfunding platform in the world, and in 2019 it was the most active investor in UK private companies. It allows all types of investors to invest as little or as much as they like in businesses they believe in and share in their success, and it allows ambitious businesses in all sectors to raise capital and build community through an efficient, online process.

Technology

Private

What are the risks?

  • Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose investors to the risk of capital losses
  • As it can take years for young businesses to fulfil their potential, this investment requires patience
  • The price of shares in the trust is determined by market supply and demand, and this may be different to the net asset value of the trust. This means the price may be volatile in response to changes in demand
  • The trust may invest in overseas securities and be exposed to currencies other than pound sterling – as a result, exchange rate movements may cause the value of the trust, individual investments, and any income paid to decrease or increase
  • The trust may invest in unquoted securities, which may be less liquid and more difficult to value, because they are generally not publicly traded – the lack of an open market may also make it more difficult to establish fair value
  • Young businesses have a different risk profile to mature blue-chip companies – risks are much more stock-specific, which implies a lower correlation with equity markets and the wider economy
  • The Company may borrow money to invest in further investments, this is known as gearing. Gearing will increase returns if the value of the investments purchased increase in value by more than the cost of borrowing, or reduce returns if they fail to do so.

Contact Schroders

Schroders is a world-class asset manager operating from 37 locations across Europe, the Americas, Asia, the Middle East and Africa.




Worldwide locations

For any further questions, please contact us. 

Contact us